| Previous Close | 32.64 |
| Open | 32.82 |
| Day High | 33.74 |
| Day Low | 31.69 |
| 52-Week High | 37.83 |
| 52-Week Low | 12.12 |
| Volume | 157,137 |
| Average Volume | 540,173 |
| Market Cap | 238.38M |
| PE | -0.81 |
| EPS | -39.55 |
| Moving Average 50 Days | 25.35 |
| Moving Average 200 Days | 25.49 |
| Change | -0.76 |
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 12, 2025 10:01 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe e
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Sep 04, 2025 8:15 PM GMT
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe
Surrozen to Present at Upcoming Healthcare Investor Conference
GlobeNewswire Inc.
Aug 06, 2025 8:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and reg